Abivax, a pioneering clinical-stage biotechnology company dedicated to innovating therapies that modulate the immune response in chronic inflammatory diseases, proudly announces a landmark funding round of $747,500,000. This substantial investment underscores the tremendous confidence investors have in Abivax’s cutting-edge approach to treating complex inflammatory conditions. At the core of this breakthrough strategy is obefazimod—an investigational, orally administered, once-daily therapy—which is currently undergoing Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Obefazimod is uniquely designed to enhance the expression of microRNA-124 (miR-124), a naturally occurring molecule that plays a crucial role in regulating the inflammatory response. By promoting miR-124, Abivax aims to stabilize immune system activity, potentially providing relief for patients who have long struggled with chronic inflammation.
The infusion of new capital will fuel further clinical research and accelerate the development of obefazimod as a transformative treatment option. In addition to advancing its Phase 3 program for ulcerative colitis, Abivax is poised to initiate a Phase 2a clinical trial to evaluate the drug’s efficacy in patients with Crohn’s disease. This strategic investment is critical in driving forward the company’s innovative therapeutic platform, which represents not only a significant leap in biotechnology but also the potential to inaugurate a whole new class of treatments—miR-124 enhancers. As Abivax continues to break new ground in the quest for effective, biology-driven solutions, this funding milestone is a promising indicator of the company’s ability to redefine care for millions of patients suffering from debilitating inflammatory conditions.
